

WHO Drug Information

Contents

General Policy Issues

- The dangers of counterfeit and substandard active pharmaceutical ingredients 123

Quality Assurance Issues

- The importance of analytical procedures in regulatory control 128

Reports on Individual Drugs

- Simplified treatment for leprosy 131
Should antibiotics be indicated for children with acute otitis media? 131
Acetylsalicylic acid: confirmed efficacy after stroke 132
Antiretroviral therapy for HIV: latest guidelines 134

General Information

- Biological standardization: report of the Expert Committee 138

Regulatory Matters

- Irinotecan-associated mortality 141
HIV protease inhibitors associated with diabetes 141
Valvular heart disease associated with fenfluramine and phentermine 141
Withdrawal of anti-diarrhoeal paediatric product 142
Dangerous products promoted on the Internet 142
Health risks of herbal products containing ephedrine 142
Photoallergic and phototoxic reactions associated with fibrates 143
Restriction on sale of high-dose vitamin B6 products 143
First-year safety reports with triple component pertussis vaccine 143

Essential Drugs

WHO Model Formulary

Antiprotozoal drugs

- Drugs used in amoebiasis 144
Diloxanide 144
Drugs used in giardiasis 145
Metronidazole 145
Drugs used in leishmaniasis 145
Meglumine antimoniate & sodium stibogluconate 146
Pentamidine 147
Amphotericin B 148
Drugs used in trypanosomiasis 148
Melarsoprol 148
Pentamidine 149
Suramin sodium 149
Eflornithine 151
Drugs used in American trypanosomiasis 151
Benznidazole 151
Nifurtimox 152

ATC/DDD Classification

(temporary)

153

Recent Publications and Documents

- Drugs for the elderly 155
Rapid examination methods against counterfeit and substandard drugs 155
Countering counterfeiting 155
Malaria: a manual for community health workers 156
Guidelines for the management of drug-resistant tuberculosis 156

Recommended International

Nonproprietary Names: List 38 157